Goldin A., Greenspan EM, Venditti JM, Schoenbach EBStudies on the biological interrelationships of folic acid, citrovorum factor, and the antimetabolite, aminopterin. J Natl Cancer Inst1952; 12: 987—1002.
2.
2. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987; 237: 178—82.
3.
Norton L., Massague J.Is cancer a disease of self-seeding?Nat Med2006; 12: 875—78
4.
Traina TA, Theodoulou M., Higgins B. et al. In vivo activity of a novel regimen of capecitabine in a breast cancer xenograft model Abstract 6071, San AntonioBreast Cancer Symposium, December, 2006.
5.
Carlson RW, Moench SJ, Hammond ME et al. Her 2 testing in breast cancer: NCCN task force report and recommendations . J Natl Compr Cancer Netw2006; 4(Suppl. 3): S1—22.
6.
Chung KY, Shia J., Kemeny NE et al. Cetuximab shows activity in colorectal cancer tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol2005; 23: 1803—10.
7.
Horowitz KB, McGuire WLPredicting response to endocrine therapy in human breast cancer: a hypothesis . Science1975; 189: 726—27.
8.
Pusztai L.Development of pharmacogenomic predictors for preoperative chemotherapy of breast cancer. Adv Exp Med Biol2006; 587: 233—49.
